Bagsværd, Denmark, 29 July 2022 - Novo Nordisk today announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes. ONWARDS
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of non-alcoholic
Bagsværd, Denmark, 3 June 2022 - Novo Nordisk today announced headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. ONWARDS
03.05.2022 - Bagsværd, Denmark, 3 May 2022 This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on .